Biogen Idec 4Q 4Q Revenues: $1.1 billion (+5%) 4Q Earnings: $306 million (+48%) FY Revenues: $4.4 billion (+7%) FY Earnings: $1.0 billion (+24%) Comments: Tysabri revenues in the quarter increased 39% to $216 million and Avonex revenues were up 5% to $596 million. Rituxan revenues in the quarter were down 15% to $257 million. Growth for the year was driven primarily by Tysabri sales, which increased 32% to $776 million, and Avonex sales, which increased 5% to $2.3 billion. Rituxan...